What this trial means for you
This study is opening soon at 1 US site. It's studying see the official record for diabetes, obesity, medication side effects.
What participants typically get: study medication (or placebo, if the trial uses one) and study-related medical care at no cost, plus close monitoring. Compensation for time and travel varies by study — ask the site. Note that in many trials you can't choose your treatment group, and some participants receive a placebo.
The study, in the sponsor's words
The objective of this project is to define and test the GenAI-powered Clinical Decision Support (CDS) tool, AIManage, providing a broad range of incretin mimetic medication management services to optimize dose titrations. The study will take place across primary care and obesity medicine clinics at NYUH. The study is currently conducting formative data collection for tool refinement (Phase 1). Once completed, a cluster randomized controlled trial of the AIManage tool will be undertaken (Phase 2).
Can you join? The exact criteria
Below is the verbatim eligibility text from the registry — bring it to your doctor; it's written for clinicians, and your own clinician is the right person to interpret it with you.
Full eligibility criteria (for you and your doctor)
Inclusion Criteria: Provider Eligibility Criteria (Phase 1) * Primary or bariatric care provider (MD/DO, NP) practicing at the participating NYULH clinics, * Provide care to at least 5 patients prescribed an IMM. Patient Eligibility Criteria (Phase 1) * (Phase 1) Currently taking an IMM or have taken an IMM in the past 6 months; * Fluency in English or Spanish; * Be willing to send/receive text messages; and * Be \> 18 years of age. Exclusion Criteria: Provider Exclusion Criteria (Phase 1) • Refuse to participate Patient Exclusion Criteria (Phase 1) • Refuse or are unable to provide informed consent;
Study sites by state
New York
- NYU Langone Health — New York
View the official record on ClinicalTrials.gov →
Follow this trial
Get an email when our monthly digest covers enrollment changes and results for trials like this one.
Newsletter signup launches soon. (Site owner: set PUBLIC_BUTTONDOWN_USERNAME in
.env to activate this form.)